<?xml version="1.0" encoding="UTF-8"?>
<p>Since vaccination is the most important strategy to combat emerging human viral infections, an effective vaccine remains a necessity, particularly for the MERS-CoV. The MERS-CoV spike (S) protein plays an essential role during virus entry through the binding of its antigenic RBD region to the DPP4 host cell receptor [
 <xref rid="B25-vaccines-07-00046" ref-type="bibr">25</xref>]. The RBD is recognized as a major antigenic glycoprotein fragment for inducing a potent humoral and cellular neutralizing antibody (nAb) immune responses [
 <xref rid="B26-vaccines-07-00046" ref-type="bibr">26</xref>,
 <xref rid="B27-vaccines-07-00046" ref-type="bibr">27</xref>,
 <xref rid="B28-vaccines-07-00046" ref-type="bibr">28</xref>,
 <xref rid="B29-vaccines-07-00046" ref-type="bibr">29</xref>,
 <xref rid="B30-vaccines-07-00046" ref-type="bibr">30</xref>,
 <xref rid="B31-vaccines-07-00046" ref-type="bibr">31</xref>].
</p>
